vs
Side-by-side financial comparison of Lucid Diagnostics Inc. (LUCD) and PLUS THERAPEUTICS, INC. (PSTV). Click either name above to swap in a different company.
PLUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.4M vs $1.2M, roughly 1.1× Lucid Diagnostics Inc.). PLUS THERAPEUTICS, INC. runs the higher net margin — -417.9% vs -858.5%, a 440.6% gap on every dollar of revenue. On growth, Lucid Diagnostics Inc. posted the faster year-over-year revenue change (3.3% vs -3.2%). Over the past eight quarters, Lucid Diagnostics Inc.'s revenue compounded faster (7.9% CAGR vs -9.7%).
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics firm focused on non-invasive screening tests for upper gastrointestinal diseases, including early detection of esophageal cancer and pre-cancerous lesions. It mainly serves healthcare providers and clinical partners across the United States, targeting at-risk patient populations.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
LUCD vs PSTV — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $1.4M |
| Net Profit | $-10.4M | $-5.7M |
| Gross Margin | — | — |
| Operating Margin | -971.0% | -420.0% |
| Net Margin | -858.5% | -417.9% |
| Revenue YoY | 3.3% | -3.2% |
| Net Profit YoY | 16.0% | -46.4% |
| EPS (diluted) | $-0.10 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $1.4M | ||
| Q3 25 | $1.2M | $1.4M | ||
| Q2 25 | $1.2M | $1.4M | ||
| Q1 25 | $828.0K | $1.1M | ||
| Q4 24 | $1.2M | $1.4M | ||
| Q3 24 | $1.2M | $1.5M | ||
| Q2 24 | $976.0K | $1.3M | ||
| Q1 24 | $1.0M | $1.7M |
| Q4 25 | — | $-5.7M | ||
| Q3 25 | $-10.4M | $-4.4M | ||
| Q2 25 | $-4.4M | $5.2M | ||
| Q1 25 | $-26.9M | $-17.4M | ||
| Q4 24 | $-11.5M | $-3.9M | ||
| Q3 24 | $-12.4M | $-2.9M | ||
| Q2 24 | $-11.0M | $-2.9M | ||
| Q1 24 | $-10.6M | $-3.3M |
| Q4 25 | — | -420.0% | ||
| Q3 25 | -971.0% | -320.8% | ||
| Q2 25 | -978.8% | -110.6% | ||
| Q1 25 | -1508.1% | -333.9% | ||
| Q4 24 | -1033.8% | -276.2% | ||
| Q3 24 | -997.8% | -260.9% | ||
| Q2 24 | -1146.7% | -289.1% | ||
| Q1 24 | -1078.1% | -196.7% |
| Q4 25 | — | -417.9% | ||
| Q3 25 | -858.5% | -316.6% | ||
| Q2 25 | -381.7% | 370.6% | ||
| Q1 25 | -3249.8% | -1643.2% | ||
| Q4 24 | -964.2% | -276.4% | ||
| Q3 24 | -1055.5% | -197.4% | ||
| Q2 24 | -1127.6% | -229.9% | ||
| Q1 24 | -1060.1% | -194.5% |
| Q4 25 | — | $0.95 | ||
| Q3 25 | $-0.10 | $-0.04 | ||
| Q2 25 | $-0.08 | $-0.01 | ||
| Q1 25 | $-0.52 | $-1.19 | ||
| Q4 24 | $-0.17 | $-0.51 | ||
| Q3 24 | $-0.25 | $-0.37 | ||
| Q2 24 | $-0.23 | $-0.71 | ||
| Q1 24 | $-0.40 | $-0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $47.3M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $25.8M | $4.0M |
| Total Assets | $53.2M | $16.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.6M | ||
| Q3 25 | $47.3M | $16.6M | ||
| Q2 25 | $31.1M | $6.9M | ||
| Q1 25 | $25.2M | $9.9M | ||
| Q4 24 | $22.4M | $3.6M | ||
| Q3 24 | $14.5M | $4.8M | ||
| Q2 24 | $24.9M | $8.4M | ||
| Q1 24 | $24.8M | $3.2M |
| Q4 25 | — | $4.0M | ||
| Q3 25 | $25.8M | $5.1M | ||
| Q2 25 | $7.9M | $3.0M | ||
| Q1 25 | $-5.4M | $-23.6M | ||
| Q4 24 | $5.4M | $-8.9M | ||
| Q3 24 | $6.3M | $-5.2M | ||
| Q2 24 | $16.0M | $-7.6M | ||
| Q1 24 | $11.9M | $-4.8M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | $53.2M | $18.7M | ||
| Q2 25 | $38.7M | $10.3M | ||
| Q1 25 | $32.8M | $12.1M | ||
| Q4 24 | $30.7M | $6.6M | ||
| Q3 24 | $22.6M | $7.0M | ||
| Q2 24 | $34.1M | $11.2M | ||
| Q1 24 | $32.0M | $5.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.9M | $-6.3M |
| Free Cash FlowOCF − Capex | — | $-6.3M |
| FCF MarginFCF / Revenue | — | -459.9% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-20.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.3M | ||
| Q3 25 | $-10.9M | $-2.5M | ||
| Q2 25 | $-10.5M | $-5.8M | ||
| Q1 25 | $-12.5M | $-6.2M | ||
| Q4 24 | $-9.9M | $-1.2M | ||
| Q3 24 | $-10.2M | $-3.7M | ||
| Q2 24 | $-11.5M | $-1.1M | ||
| Q1 24 | $-12.6M | $-4.5M |
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-5.8M | ||
| Q1 25 | — | $-6.2M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.7M | ||
| Q2 24 | — | $-1.2M | ||
| Q1 24 | — | $-4.6M |
| Q4 25 | — | -459.9% | ||
| Q3 25 | — | -184.3% | ||
| Q2 25 | — | -417.6% | ||
| Q1 25 | — | -583.1% | ||
| Q4 24 | — | -86.5% | ||
| Q3 24 | — | -253.7% | ||
| Q2 24 | — | -96.2% | ||
| Q1 24 | — | -271.5% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.13× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
